Table 3. FAF Imaging and Clinical Characteristics of Patients.

Patient No./ Sex/Age, y	Diagnosis	Eye	Visual Acuity	Funduscopic Examination Findings	FAF Findings	Follow-up, mo	Therapy
1/M/31	SPC	OD	20/20	CRA extending from peripapillary area into macula	HOAF corresponding to CRA, HRAF in active region	13	Prednisone, azathioprine sodium, cyclosporine, POT
1/M/31	SPC	OS	20/16	CRA extending from peripapillary area nasally	HOAF corresponding to CRA		Prednisone, azathioprine sodium, cyclosporine, POT
2/M/60	SPC	OD	20/125	CRA extending from peripapillary region involving macula	HOAF corresponding to CRA, HRAF in active region	4	Prednisone, azathioprine, cyclosporine, POT
2/M/60	SPC	OS	20/80	CRA extending from peripapillary region involving macula, nasal retina	HOAF corresponding to CRA, HRAF in active region		Prednisone, azathioprine, cyclosporine, POT
3/F/41	SPC	OD	20/125	CRA	Diffuse HOAF	11	Prednisone, azathioprine, cyclosporine
3/F/41	SPC	OS	20/25	Peripheral CRA and mottling	Focal HOAF in area of CRA		Prednisone, azathioprine, cyclosporine
4/F/42	SPC	OD	1′/200E	Macular RPE scarring and CRA	Diffuse HOAF	8	Sirolimus, POT, bevacizumab
4/F/42	SPC	OS	20/20	Macular RPE scarring, RPE hyperplasia, and CRA	Mottled HOAF, HRAF in region of CNV		Sirolimus, POT, bevacizumab
5/M/58	SPC	OD	20/50	CRA involving macula and midperipheral retina	HOAF corresponding to CRA	NA
5/M/58	SPC	OS	20/63	CRA involving macula and midperipheral retina	HOAF corresponding to CRA
6/M/28	Presumed TB-SPLC	OS	20/20	Widespread RPE hyperpigmentation and atrophy	Complex pattern of HOAF and HRAF within macula and midperipheral retina	NA	RIPE
7/M/68	MFC	OD	20/125	Punched-out CR lesions involving macula and periphery	HOAF corresponding to CR lesions	12	Mycophenolate mofetil
7/M/68	MFC	OS	20/20	Punched-out CR lesions involving macula and periphery	HOAF corresponding to CR lesions
8/M/44	MFC	OD	20/50	PPA and multiple punched-out peripheral CR lesions	Perivascular HOAF involving macula and periphery, some corresponding to CR lesions	NA
8/M/44	MFC	OS	20/63	PPA and multiple punched-out peripheral CR lesions	Perivascular HOAF involving macula and periphery, some corresponding to CR lesions
9/F/43	MFC	OD	HM	PPA and multiple peripheral CR lesions	Diffuse HOAF spots, greater than visualized with fundus photography	NA
9/F/43	MFC	OS	20/80	PPA and multiple peripheral CR lesions	Diffuse HOAF spots, greater than visualized with fundus photography
10/F/24	MFC	OD	20/32	Foveal RPE hyperpigmentation, RPE mottling, and peripheral CR lesions	HOAF during active phase and quiescence	11	Cyclosporine
10/F/24	MFC	OS	20/25	Foveal RPE hyperpigmentation, RPE mottling, and peripheral CR lesions	HRAF during active phase, HOAF during quiescence
11/F/44	MFC/PIC	OD^a	20/200	Macular scarring and RPE hyperplasia	Macular HOAF	12	Sirolimus
11/F/44	MFC/PIC	OS^a	20/160	Macular scarring and RPE hyperplasia	Macular HOAF
12/F/35	MFC/PIC	OD^a	20/12.5	Graying of RPE in region of CNVM, few areas of CRA	HRAF in area of CNVM activity, some HOAF spots	NA	Sirolimus
12/F/35	MFC/PIC	OS^a	20/80	CRA and RPE hyperplasia	HOAF corresponding to scarring, mild persistent perifoveal HRAF
13/M/74	MFC	OD	20/32	CRA involving macula and peripheral retina	HOAF corresponding to CRA in macula, peripheral retina	12	Methotrexate sodium
13/M/74	MFC	OS	20/40	CRA involving macula and peripheral retina	HOAF corresponding to CRA in macula, peripheral retina
14/F/28	MFC	OD	20/20	Multifocal, peripheral hyperpigmented spots	HOAF corresponding to lesions with granular HRAF within each lesion (active)	NA
14/F/28	MFC	OS	20/20	Multifocal, peripheral hyperpigmented spots	HOAF corresponding to lesions with granular HRAF within each lesion (active)
15/F/56	BRC	OD	20/20	Multiple atrophic CR lesions within macula	Multiple HOAF dots within macula	13	Cyclosporine, mycophenolate mofetil
15/F/56	BRC	OS	20/20	Multiple atrophic CR lesions within macula	Multiple HOAF dots within macula		Cyclosporine, mycophenolate mofetil
16/M/35	BRC	OD	20/25	Multiple atrophic CR lesions involving periphery, few macular lesions	Diffuse HOAF involving macula and peripapillary area	NA	Cyclosporine
16/M/35	BRC	OS	20/20	Multiple atrophic CR lesions involving periphery, few macular lesions	HOAF of nasal peripapillary region
17/M/49	BRC	OD	20/50	Multiple CR lesions in various stages of healing	Macular HOAF	NA
17/M/49	BRC	OS	20/250	CRA in region of prior laser treatment, numerous pigmented CR lesions	HOAF corresponding to laser scar and CR lesions
18/F/56	BRC	OD	20/50	Few atrophic CR lesions inferior to nerve and inferior macula	HOAF of CR lesions inferior to nerve and inferior macula	8	Cyclosporine, mycophenolate mofetil, daclizumab, prednisone
18/F/56	BRC	OS	20/25	Few atrophic lesions inferior to nerve and nasal periphery	HOAF of CR lesions inferior to nerve and nasal periphery		Cyclosporine, mycophenolate mofetil, daclizumab, prednisone
19/F/58	BRC	OD	20/25	Few peripheral CR lesions, ERM	Few areas of peripheral HOAF	7	Mycophenolate mofetil
19/F/58	BRC	OS	20/32	Few peripheral CR lesions	Few areas of peripheral HOAF
20/M/33	BRC	OD	20/25	Few CR lesions, ERM	Plaquelike zones of HRAF within macula (nonfoveal)	7	Daclizumab
20/M/33	BRC	OS	20/25	Few CR lesions inferior and inferonasal to nerve	Plaquelike zones of HRAF within macula (nonfoveal)
21/M/57	BRC	OD	20/32	PPA, few atrophic-appearing CR lesions	Mixed HOAF and HRAF temporal to nerve involving inferonasal macula, HOAF of PPA	NA	Mycophenolate mofetil
21/M/57	BRC	OS	20/25	PPA	HOAF of area of PPA
22/M/70	BRC	OD^b	20/200	Multiple atrophic CR spots, RPE hyperpigmentation/mottling	HRAF dots mixed with HOAF (involving macula including foveal region)	NA	Daclizumab
22/M/70	BRC	OS	20/40	Multiple atrophic CR spots, RPE atrophy adopting perifoveal distribution	HOAF dots temporal to fovea, HOAF in areas of atrophic CR lesions
23/F/52	BRC	OD	20/25	Multiple oval CR lesions involving peripheral retina	Minimal HOAF spots <1 DD (fewer than seen on clinical examination)	NA	Daclizumab
23/F/52	BRC	OS	20/80	Multiple oval CR lesions involving retinal periphery and few in posterior pole	Few HOAF spots (fewer than seen on clinical examination)
24/M/53	BRC	OD	20/800	Large zonal regions of CRA, few atrophic CR lesions peripherally	HOAF temporal to fovea, diffuse HOAF peripherally	8	Daclizumab
24/M/53	BRC	OS	20/800	Large zonal regions CRA, few atrophic CR lesions peripherally	HOAF temporal to fovea, diffuse HOAF peripherally
25/F/36	AZOOR	OD	20/25	Zonal regions of RPE loss	Peripapillary HOAF halo with surrounding HRAF rim	10
25/F/36	AZOOR	OS	20/20	Zonal regions of RPE loss	Peripapillary HOAF halo with surrounding HRAF rim, macular HOAF lesion with HRAF rim
26/F/57	AZOOR	OD	20/40	Large zonal region of RPE atrophy and hyperpigmentary change at border of lesion	Macular HOAF with granular HRAF peripherally	NA
26/F/57	AZOOR	OS	20/20	Superonasal area of CR atrophy	Minimal nasal peripapillary granular HRAF and HOAF
27/M/48	APMPPE	OD	20/32	Multiple placoid macular lesions with RPE hyperpigmentation and some fibrosis	Placoid HOAF lesions involving macula	NA
27/M/48	APMPPE	OS	20/200	Multiple placoid macular lesions with RPE hyperpigmentation and some fibrosis	Placoid HOAF lesions involving macula
28/M/36	RPC	OD	20/160	Multiple placoid areas of RPE hyperplasia and CRA	Widespread HOAF involving macula and peripheral retina	NA	Mycophenolate mofetil
28/M/36	RPC	OS	20/160	Multiple placoid areas of RPE hyperplasia and CRA	Widespread HOAF involving macula and peripheral retina

Abbreviations: CNV, choroidal neovascularization; CNVM, choroidal neovascular membrane; CR, chorioretinal; CRA, chorioretinal atrophy; DD, disc diameter; ERM, epiretinal membrane; FAF, fundus autofluorescence; HOAF, hypoautofluorescence; HRAF, hyperautofluorescence; NA, not available; PIC, punctate inner choroidopathy; POT, periocular triamcinolone acetonide; PPA, peripapillary atrophy; RIPE, 4-drug antituberculosis therapy consisting of rifampin, isoniazid, pyrimethamine, and ethambutol hydrochloride; RPE, retinal pigment epithelium. For other abbreviations, see Table 1.

Associated ophthalmic diagnoses included CNVM.

Associated ophthalmic diagnoses included vitreomacular traction.